Format

Send to

Choose Destination
Biochem Pharmacol. 2010 May 15;79(10):1379-86. doi: 10.1016/j.bcp.2010.01.013. Epub 2010 Jan 22.

Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging.

Author information

1
Department of Surgery, Columbia University, New York, NY 10032, United States.

Abstract

The multi-ligand Receptor for Advanced Glycation Endproducts (RAGE) is implicated in the pathogenesis and progression of chronic diseases such as diabetes and immune/inflammatory disorders. Recent studies are uncovering the precise mechanisms by which distinct RAGE ligands bind the extracellular (soluble) domain of the receptor at the V-, C1- and/or C2-immunoglobulin like domains. Experiments using soluble RAGE in animals as a ligand decoy have illustrated largely beneficial effects in reducing vascular and inflammatory stress and, thereby, preventing long-term tissue damage in models of diabetes and immune/inflammatory disorders. Measurement of soluble RAGE levels in the human, both "total" soluble RAGE and a splice variant-derived product known as endogenous secretory or esRAGE, holds promise for the identification of potential therapeutic targets and/or biomarkers of RAGE activity in disease. In this article, we review the evidence from the rodent to the human implicating RAGE in the diverse disease states in which its ligands accumulate.

PMID:
20096667
PMCID:
PMC2854502
DOI:
10.1016/j.bcp.2010.01.013
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center